Results 181 to 190 of about 885,361 (302)

Stress exposure prior to diagnosis and clinical characteristics in systemic lupus erythematosus: a cross-sectional study. [PDF]

Rheumatol Int
Papachristodoulou E, Kakoullis L, Christophi CA, Derk CT, Chatzittofis A, Alexopoulos P, Karanikolas M, Velissaris D, Parperis K.   +8 more
europepmc   +1 more source

Dnmt3a Mutations Limit Normal and Autoreactive CD4+ T Follicular Helper Responses and Attenuate T Cell–Driven Joint Inflammation

Arthritis &Rheumatology, EarlyView.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen, Sanjaykumar Boddul, Zhaojun Li, Zsolt Kasza, Marlene Schülein, Bruno Raposo, Karine Chemin, Per‐Johan Jakobsson, Alexander Espinosa, Lars Klareskog, Fredrik Wermeling   +10 more
wiley   +1 more source

Epidemiology changes in systemic lupus erythematosus in Italy: the EASIEST study. [PDF]

Lupus Sci Med
Gasparotto M, Mattioli I, Alti E, Biancalana E, Canfora M, Chiara E, Di Maso V, Duro G, Ferraro A, Lisi M, Malandrino D, Palmerini M, Urban ML, Vrola L, Silvestri E, Bettiol A, Emmi G.   +16 more
europepmc   +1 more source

Age‐Associated B Cells Contribute to Inflammation Via Antibody‐Independent Mechanisms in Takayasu Arteritis

Arthritis &Rheumatology, EarlyView.
Objective Although Takayasu arteritis (TAK) is not a prototypical autoantibody‐mediated disease, accumulating evidence suggests that B cells are involved. This study aimed to investigate the pathway of B cell activation and its contributions to TAK pathogenesis. Methods Histologic analysis of paravascular lymph nodes and affected arteries was conducted
Chenglong Fang, Xiaoxi Yang, Xiaochuan Sun, Shangyi Jin, Lihong Du, Jinwei Gao, Jing Li, Zhen Chen, Yuexin Chen, Mengtao Li, Xinping Tian   +10 more
wiley   +1 more source

Bullous Systemic Lupus Erythematosus as a Marker of Treatment-Refractory Systemic Disease: A Case Report. [PDF]

Cureus
Izadian Bidgoli A, Gomez Veliz A, Mathew J, De Guzman J, Yazdanpanah S, Joshi A.   +5 more
europepmc   +1 more source

Type I Interferon Drives Dysfunction of a Distinct CD8+ HLA‐DRB1+ T Cell Subset in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long, Elio Carmona, Mikhail G. Dozmorov, Amr H. Sawalha   +3 more
wiley   +1 more source

Vitamin D deficiency in newly diagnosed childhood-onset systemic lupus erythematosus: prevalence and clinical associations. [PDF]

Eur J Pediatr
Ratanaphisit T, Sukharomana M, Piyaphanee N, Tangcheewinsirikul S, Charuvanij S.   +4 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Serum CXCL10 as a potential biomarker for lupus nephritis and disease activity: evidence from an Egyptian cohort. [PDF]

BMC Nephrol
Badr FM, Gamal DM, Mohsen GM, Teama MAEM.   +3 more
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source